Liraglutide
FDA ApprovedThe first long-acting GLP-1 receptor agonist, FDA-approved for type 2 diabetes (Victoza, 2010) and chronic weight management (Saxenda, 2014). Pioneered the therapeutic class with proven cardiovascular benefits in the landmark LEADER trial.
Victoza · Saxenda · NN2211
58 human studies
- Preclinical
- 19%
- Clinical
- 81%
Based on 72 cited sources
clinically demonstrated · high confidence
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 97 (1A35/1B24/1C15/1D15/1E8): meta-analyses of multiple low-RoB Phase 3 RCTs — LEADER (27295427, double-blind, N=9,340), SCALE (26132939, double-blind, N=3,731), the 6-trial LEAD program (>4,000) and LEAD-6 (19515413, 15-country active-comparator) — total human N far exceeds 1,000 with direct population/route/outcome match; substantial but not extensive preclinical base caps 1E. Mechanism 96 (2A40/2B28/2C18/2D10): GLP-1R binding plus functional confirmation and neuron-specific POMC/CART GLP-1R mediation of weight loss (Secher 25202980), full target-to-effect pathway, in-vivo monotonic dose-response (1.8mg vs 3.0mg). Plausibility 96 (3A38/3B25/3C20/3D13): full mechanism->surrogate->clinical chain proven for HbA1c, weight and MACE (LEADER 27295427), fully coherent with incretin physiology, multiple same-class analogues (semaglutide, tirzepatide, exenatide) reproduce the effect. Global Coverage 97 (4A34/4B24/4C24/4D15): reproduced across many independent groups and countries, >100 studies, multi-regulator approval. Community Experience 85 (5A30/5B30/5C16/5D9): >7 years population-level use since 2010, broadly consistent reports, but recurring titration GI plus a rodent thyroid C-cell boxed warning and rare pancreatitis cap 5D. Effectiveness basis clinical (high): SCALE 8.4kg vs 2.8kg placebo (~5.6% placebo-adjusted), 63% achieve >=5% and 33% >10% weight loss, exceeding the ~5% MCID on hard patient-relevant outcomes; superior to placebo and non-inferior/superior to exenatide (LEAD-6) but modest versus newer agents (semaglutide, tirzepatide) head-to-head, placing it mid-tier on comparative effectiveness.
Liraglutide is an FDA-approved GLP-1 receptor agonist with extensive human clinical trial data. Its mechanisms are well-characterized through over 15 years of clinical use.
How It Works (Simplified)
Liraglutide mimics the natural incretin hormone GLP-1 with modifications that extend its action:
Activates GLP-1 receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion only when blood sugar is elevated.
Acts on hypothalamic GLP-1 receptors to reduce hunger signals and increase feelings of fullness, leading to reduced caloric intake.
Delays gastric emptying, prolonging satiety after meals and reducing postprandial blood glucose spikes.
Provides multifactorial CV benefits through blood pressure reduction, anti-inflammatory effects, and potential direct cardioprotection.
Key Research: Marso SP et al. (LEADER Trial, 2016) demonstrated 13% reduction in major adverse cardiovascular events in high-risk T2D patients. PMID:27295427
Important Limitations
- Common GI side effects (nausea, vomiting) especially during titration
- Requires daily subcutaneous injection (less convenient than weekly alternatives)
- Boxed warning for thyroid C-cell tumors (based on rodent studies; human relevance uncertain)
- Contraindicated in personal/family history of medullary thyroid carcinoma or MEN2
- Weight regain typically occurs after discontinuation
- Less effective for weight loss than newer agents (semaglutide, tirzepatide)
Reported positives
- Moderate appetite suppression with well-characterized profile
- Daily dosing allows finer control compared to weekly options
- Long track record of real-world use since 2010
- Generic availability improving access and affordability
Reported negatives
- Weight loss modest compared to newer GLP-1 agents
- Daily injection burden cited as major drawback
- Nausea common especially during titration
- Many users switched to weekly alternatives for convenience
“First-generation GLP-1 with extensive real-world data. Community increasingly favors weekly alternatives.”
Self-reported, unverified accounts — not clinical evidence and no substitute for the cited research. Anecdotes are prone to selection bias and placebo effects.
Initial dose titration phase. Most patients experience transient nausea (25-40%) which typically improves. Early appetite suppression and reduced food intake begin. Blood glucose effects start within days.
PMID:19515413GI side effects diminish as tolerance develops. Weight loss becomes measurable (1-2 kg). HbA1c begins declining. Patients should reach target dose (1.8mg or 3.0mg) by end of this period.
PMID:21205128Steady weight loss continues. HbA1c reduction of 0.5-1.0% typically achieved. Full appetite suppression effects established. Most GI tolerability issues resolved.
PMID:26132939Maximum weight loss typically reached around weeks 40-56 (average 8% with 3.0mg dose). HbA1c maintained at 1.0-1.5% below baseline. Cardiovascular benefits emerge with longer-term use.
PMID:27295427Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Ipamorelin
CompatibleDifferent mechanisms (GLP-1 vs GHRP). Ipamorelin stimulates GH release while liraglutide affects glucose and satiety. No known direct interactions.
Tesamorelin
CompatibleTesamorelin is a GHRH analog targeting GH secretion. Different mechanism from liraglutide's GLP-1 agonism. Both may reduce visceral fat through different pathways.
BPC-157
CautionBoth affect GI function. BPC-157 is gastroprotective while liraglutide slows gastric emptying. Unclear if effects interact; monitor GI symptoms if combined.
Semaglutide
AvoidBoth are GLP-1 receptor agonists. Concurrent use would result in overlapping mechanisms and increased risk of adverse effects including severe nausea, vomiting, and potential hypoglycemia. Never combine GLP-1RAs.
Tirzepatide
AvoidTirzepatide is a dual GIP/GLP-1 agonist. Combining with liraglutide would cause receptor overstimulation, severe GI effects, and no additional therapeutic benefit. Choose one or the other.
Exenatide
AvoidBoth are GLP-1 receptor agonists with overlapping mechanisms. Do not combine. Exenatide is shorter-acting but targets the same receptor pathway.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Liraglutide
Related Peptides
5-Amino-1MQ
5-Amino-1-Methylquinolinium · NNMT Inhibitor
A small molecule NNMT inhibitor studied for metabolic effects in animal models. No human clinical trials have been conducted. Increases NAD+ levels in adipose tissue in preclinical studies.
Amycretin
NNC0487-0111 · Oral Amycretin · Subcutaneous Amycretin
A novel single-molecule dual GLP-1/amylin receptor agonist developed by Novo Nordisk. Unlike CagriSema (a fixed-dose combination), amycretin is a unified peptide that activates both pathways. Phase 1 trials showed superior weight loss signals versus semaglutide, with both oral and subcutaneous formulations in development.
AOD-9604
Anti-Obesity Drug 9604 · Tyr-hGH Fragment 177-191 · hGH Fragment 176-191
A modified fragment of human growth hormone (amino acids 176-191 with N-terminal tyrosine) studied for fat loss. Clinical development discontinued after Phase 2b/3 trials failed to show efficacy in 536 subjects. Now prohibited by WADA and excluded from FDA compounding.
Cagrilintide
AM833 · NN9838
A long-acting amylin analog developed by Novo Nordisk for weight management. Studied in Phase 3 trials as CagriSema (combination with semaglutide). The Phase 3 REDEFINE 1 trial showed -20.4% weight loss with cagrilintide-semaglutide versus -3.0% with placebo at 68 weeks.
CagriSema
Cagrilintide-Semaglutide · NNC0174-0833
A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) for chronic weight management. Phase 3 REDEFINE trials demonstrate 20-23% weight loss at 68 weeks. NDA submitted to FDA December 2025. First GLP-1/amylin combination therapy.
CT-388
RG-6912
A dual GLP-1/GIP receptor agonist (INN enicepatide; also RO7795068) acquired by Roche through the $2.7 billion Carmot Therapeutics acquisition in 2024. The published Phase 1 trial (NCT04838405) showed 4.7-8.0% mean weight loss vs 0.5% placebo over 4 weeks; a more widely reported ~18.8% placebo-adjusted figure at 24 weeks comes from an unpublished Phase 1 extension reported via press release. Phase 2 obesity and T2D trials are completed or ongoing and Phase 3 began in 2026, positioning it as a competitive obesity therapeutic with a mechanism similar to tirzepatide.